Key Points
- Insider sale: Director David Mulham sold 873 shares on December 10 at an average price of $21, reducing his stake by 9.43% to 8,387 shares (worth about $176,127), according to an SEC filing.
- USNA shares traded down to $20.79 (‑0.4%) on light volume; the company has a market cap of ~$380 million, a trailing P/E of 23.6, and 50-/200-day moving averages of $20.66 and $27.13 respectively.
- Recent results showed Q (last reported) EPS of $0.56 on $200.2M revenue, management set Q3 2025 guidance at ‑0.15 to 0.15 EPS, and analysts carry a consensus rating of Reduce with an average price target of $36.00.
USANA Health Sciences, Inc. (NYSE:USNA - Get Free Report) insider David Mulham Mulham sold 873 shares of the stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $21.00, for a total value of $18,333.00. Following the completion of the transaction, the insider directly owned 8,387 shares of the company's stock, valued at $176,127. This trade represents a 9.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
USANA Health Sciences Stock Down 0.4%
USNA stock traded down $0.08 during trading on Friday, reaching $20.79. 1,060 shares of the company's stock were exchanged, compared to its average volume of 192,989. USANA Health Sciences, Inc. has a 1-year low of $18.48 and a 1-year high of $38.32. The firm has a market cap of $380.04 million, a PE ratio of 23.63, a P/E/G ratio of 1.01 and a beta of 0.66. The company's fifty day moving average price is $20.66 and its 200-day moving average price is $27.13.
USANA Health Sciences (NYSE:USNA - Get Free Report) last issued its quarterly earnings data on Thursday, October 9th. The company reported $0.56 earnings per share for the quarter. The business had revenue of $200.22 million for the quarter. USANA Health Sciences had a net margin of 1.86% and a return on equity of 6.97%. USANA Health Sciences has set its Q3 2025 guidance at -0.150--0.150 EPS. As a group, sell-side analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
USNA has been the subject of several recent analyst reports. Wall Street Zen cut shares of USANA Health Sciences from a "buy" rating to a "hold" rating in a report on Saturday, October 11th. Zacks Research upgraded USANA Health Sciences from a "strong sell" rating to a "hold" rating in a research report on Tuesday. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of USANA Health Sciences in a research note on Monday. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and an average price target of $36.00.
Read Our Latest Research Report on USNA
Institutional Trading of USANA Health Sciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE boosted its holdings in USANA Health Sciences by 13.1% during the first quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after buying an additional 535 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of USANA Health Sciences by 339.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock valued at $27,000 after acquiring an additional 771 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of USANA Health Sciences by 23.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 173,997 shares of the company's stock worth $4,693,000 after acquiring an additional 33,141 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of USANA Health Sciences in the 1st quarter worth $870,000. Finally, Nuveen LLC acquired a new position in shares of USANA Health Sciences in the 1st quarter worth $895,000. 54.25% of the stock is owned by institutional investors and hedge funds.
About USANA Health Sciences
(
Get Free Report)
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
